Table 2.
Summary of tolerability on the day of treatment by indication
| NGX-4010 | ||||
|---|---|---|---|---|
| PHN (n = 919) | HIV-DSP (n = 685) | PDN (n = 91) | Total (n = 1696) | |
| Maximum change in NPRS scorea during topical anesthetic application, mean (SD) | −1.6 (2.0) | −1.0 (1.6) | −1.4 (1.8) | −1.3 (1.8) |
| Maximum change in NPRS scorea during and after patch application,b mean (SD) | 2.8 (2.7) | 2.3 (2.7) | 2.3 (3.1) | 2.6 (2.7) |
| Subjects with an increase in NPRS score of >2 points on day 0,b n (%) | 477 (52) | 299 (44) | 42 (46) | 818 (48) |
| Subjects completing at least 90% of the intended patch application duration, n (%) | 901 (98) | 681 (99) | 91 (100) | 1673 (99) |
| Subjects using medication for treatment-related pain on days 0–5, n (%) | 451 (49) | 460 (67) | 13 (14) | 924 (55) |
a
Notes: Change from preanesthetic time point;
b
includes the evening of the treatment day.
Abbreviations: HIV-DSP, human immunodeficiency virus-distal sensory polyneuropathy; NPRS, Numeric Pain Rating Scale; PDN, painful diabetic neuropathy; PHN, postherpetic neuralgia; SD, standard deviation.